Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Frontage Holdings Corp. ( (HK:1521) ) has issued an update.
Frontage Holdings Corporation has announced a leadership change effective January 6, 2025, where Dr. Abdul Mutlib will step down as CEO and transition to an advisory role, while Dr. Wentao Zhang and Dr. Zhongping Lin are appointed as Co-CEOs. This strategic move is part of the company’s leadership succession plan, aimed at ensuring continuity and fostering growth, with Dr. Mutlib continuing to support the company in an advisory capacity.
More about Frontage Holdings Corp.
Frontage Holdings Corporation, incorporated in the Cayman Islands, operates in the biotechnology and pharmaceutical industry, providing drug discovery and development services through its subsidiaries, including Frontage Laboratories, Inc.
YTD Price Performance: -11.24%
Average Trading Volume: 3,017,969
Technical Sentiment Consensus Rating: Sell
Current Market Cap: HK$3.22B
See more data about 1521 stock on TipRanks’ Stock Analysis page.